Timothy J. Panella

661 total citations
27 papers, 563 citations indexed

About

Timothy J. Panella is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Timothy J. Panella has authored 27 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Timothy J. Panella's work include Melanoma and MAPK Pathways (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Research and Treatments (3 papers). Timothy J. Panella is often cited by papers focused on Melanoma and MAPK Pathways (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Research and Treatments (3 papers). Timothy J. Panella collaborates with scholars based in United States, United Kingdom and Italy. Timothy J. Panella's co-authors include Robert L. Fine, D L Trump, David C. Smith, S. Clifford Schold, Eric P. Winer, M. Perenna Rogers, Peter Ellis, V. Craig Jordan, R. Eric Heidel and John L. Bell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Timothy J. Panella

25 papers receiving 547 citations

Peers

Countries citing papers authored by Timothy J. Panella

Since Specialization

Citations

This map shows the geographic impact of Timothy J. Panella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy J. Panella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy J. Panella more than expected).

Fields of papers citing papers by Timothy J. Panella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy J. Panella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy J. Panella. The network helps show where Timothy J. Panella may publish in the future.

Co-authorship network of co-authors of Timothy J. Panella

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy J. Panella. A scholar is included among the top collaborators of Timothy J. Panella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy J. Panella. Timothy J. Panella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oral microbiome and mycobiome dynamics in cancer therapy-induced oral mucositis 2025 ·Scientific Data ·Laurentia Nodit, (unknown), Timothy J. Panella, (unknown), (unknown), (unknown), (unknown), Dawn M. Klingeman, (unknown), Alyssa A. Carrell, Mircea Podar	0
2	First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study 2024 ·European Journal of Cancer ·(unknown), Konstantin Penkov, Meredith McKean, Mario Mandalà, (unknown), Timothy J. Panella, Tibor Csőszi, (unknown), (unknown), (unknown), Alessandra di Pietro, Dirk Schadendorf	5
3	A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). 2023 ·Journal of Clinical Oncology* ·Diwakar Davar, Alexandra P. Ikeguchi, Elizabeth I. Buchbinder, Alexander N. Shoushtari, (unknown), Eric Bernicker, Sarah A. Weiss, Gregory A. Daniels, Timothy J. Panella, (unknown), Howard Goodall, Ryan J. Sullivan	4
4	A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma. 2023 ·Journal of Clinical Oncology ·Timothy J. Panella, Sajeve Thomas, Meredith McKean, Kim Margolin, Ryan Weight, (unknown), (unknown), (unknown), Mark Salvati, Israel Lowy, Matthew G. Fury, Giuseppe Gullo	1
5	Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI). 2023 ·Journal of Clinical Oncology ·Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy J. Panella, Meredith McKean, Edgardo S. Santos, Jill S. Clancy, (unknown), Anna Polli, Alessandra di Pietro, Paolo A. Ascierto	1
6	Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). 2021 ·Journal of Clinical Oncology ·Alain P. Algazi, (unknown), William P. Smith, Timothy J. Panella, Dong M. Shin, Justine Y. Bruce, (unknown), Jean S. Campbell, Lauren Abell, (unknown), (unknown), Robert H. Pierce, Ann W. Gramza	1
7	349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) 2020 ·SHILAP Revista de lepidopterología ·Alain P. Algazi, William D. Smith, Timothy J. Panella, Dong M. Shin, (unknown), (unknown), (unknown), Jean S. Campbell, Robert H. Pierce, Michael J. Guarino	0
8	A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma. 2017 ·Journal of Clinical Oncology ·William J. Edenfield, Carlos Becerra, Fadi S. Braiteh, Alexander I. Spira, Ryan J. Sullivan, Timothy J. Panella, (unknown), (unknown), Youzhi Li, Keith T. Flaherty, Matthew Hitron, Chiang Li	4
9	Is the TNM Staging System for Breast Cancer Still Relevant in the Era of Biomarkers and Emerging Personalized Medicine for Breast Cancer - An Institution's 10-year Experience 2015 ·The Breast Journal ·Amila Orucevic, Jason Chen, James M. McLoughlin, R. Eric Heidel, Timothy J. Panella, John L. Bell	25
10	Breast Cancer in Elderly Caucasian Women—An Institution-Based Study of Correlation between Breast Cancer Prognostic Markers, TNM Stage, and Overall Survival 2015 ·Cancers ·Amila Orucevic, (unknown), (unknown), R. Eric Heidel, James M. McLoughlin, Timothy J. Panella, John L. Bell	4
11	Prognostic Value of Breast Cancer Subtypes, Ki-67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian Women 2012 ·The Breast Journal ·(unknown), John L. Bell, R. Eric Heidel, (unknown), (unknown), Lisa Duncan, (unknown), Timothy J. Panella, Amila Orucevic	73
12	Metastasis of squamous cell carcinoma of the bladder to the heart: Case report and review of the literature 2006 ·Urology ·Wesley M. White, W. Bedford Waters, Timothy J. Panella, Frederick A. Klein	5
13	RELATIVE SEDIMENTATION OF HEMATOPOIETIC PROGENITORS IN HUMAN CORD BLOOD, PERIPHERAL BLOOD, AND BONE MARROW AS DETERMINED BY COUNTERFLOW CENTRIFUGAL ELUTRIATION1 1998 ·Transplantation ·N. Gengozian, (unknown), Michael R. Caudle, Timothy J. Panella	1
14	<title>Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer</title> 1998 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Markus F. Renschler, Alan R. Yuen, Timothy J. Panella, (unknown), (unknown), Laura J. Esserman, Masoud Panjehpour, (unknown), Victor H. Fingar, Elizabeth Lowe, J Engel, Bert L. Lum, Kathryn W. Woodburn, Wai‐Fung Cheong, Richard Miller	22
15	Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060 1996 ·Cancer ·Elizabeth Poplin, Joth Jacobson, Arnold Herskovic, Timothy J. Panella, Manuel Valdivieso, Laura F. Hutchins, John S. Macdonald	3
16	Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study 1995 ·Investigational New Drugs ·Stephen K. Williamson, John J. Crowley, Robert B. Livingston, Timothy J. Panella, J. Wendall Goodwin	17
17	High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine 1992 ·JNCI Journal of the National Cancer Institute ·D L Trump, David C. Smith, Peter Ellis, M. Perenna Rogers, S. Clifford Schold, Eric P. Winer, Timothy J. Panella, V. Craig Jordan, Robert L. Fine	186
18	Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. 1992 ·PubMed ·Timothy J. Panella, David C. Smith, S. Clifford Schold, M. Perenna Rogers, Eric P. Winer, Robert L. Fine, Joanna Crawford, (unknown), D L Trump	24
19	Absence of phosphatidylinositol (PI)‐linked proteins in a very early human multipotential haematopoietic marrow cell 1991 ·British Journal of Haematology ·Andrew T. Huang, Timothy J. Panella, (unknown), Wendell F. Rosse	4
20	Platelets acquire a secretion defect after high-dose chemotherapy 1990 ·Cancer ·Timothy J. Panella, William P. Peters, James G. White, Yusuf A. Hannun, Charles S. Greenberg	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact